Clinical Trials Browser

Phase 1/2 × Has announcements × naxitamab × Clear all

NCT01757626 2026-01-07

Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Phase 1/2 Active not recruiting

186 enrolled 1 FDA

Neuroblastoma